Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1682 1693
This examiner grants 0% of resolved cases
Kendra Raychell Vann-Ojuekaiye is an examiner in Tech Center 1600 and Art Unit 1682, with a limited sample of 21 resolved cases. Her allowance rate is 0.0%, which indicates an extremely challenging path to grant. This 0.0% rate suggests that none of the applications on her docket have resulted in an allowance in the current dataset. The 21 cases provide a preliminary but stark look at the prosecution environment under her review.
The data also reveals an interview lift of 0.0%, suggesting that interviews have not yet resulted in an allowance for this examiner. Furthermore, the median days to allowance is 1381, which is the timeline for the prosecution process in this art unit. The lack of any allowances and the 0.0% lift indicate that standard prosecution strategies have not yet been successful. The 1381-day median pendency is a key consideration for applicants navigating this difficult docket.
Practitioners should approach Art Unit 1682 with extreme caution given the 0.0% allowance rate. The 0.0% interview lift suggests that verbal advocacy has not yet provided a path to success. With only 21 cases resolved, the data is still developing, but the current trend is exceptionally restrictive. Applicants should be prepared for a very difficult journey, keeping the 1381-day median in mind for the duration of the prosecution process in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17908279 | PREDICTION OF RADIOTHERAPY RESPONSE FOR PROSTATE CANCER SUBJECT BASED ON T-CELL RECEPTOR SIGNALING GENES | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 17561408 | MOLECULAR SUBTYPING, PROGNOSIS, AND TREATMENT OF BLADDER CANCER | Non-Final OA | The University of British Columbia |
| 18553312 | METHODS FOR ASSESSING PROLIFERATION AND ANTI-FOLATE THERAPEUTIC RESPONSE | Non-Final OA | The University of North Carolina at Chapel Hill |
| 17413802 | TILED ASSAYS USING CRISPR-CAS BASED DETECTION | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18296915 | TRANSMEMBRANE SENSORS AND MOLECULAR AMPLIFIERS FOR LYSIS-FREE DETECTION OF INTRACELLULAR TARGETS | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18113481 | POOLED OPTICAL SCREENING AND TRANSCRIPTIONAL MEASUREMENTS OF CELLS COMPRISING BARCODED GENETIC PERTURBATIONS | Final Rejection | Insitro, Inc. |
| 17486936 | METHODS FOR MODIFYING TRANSLATION | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 17995058 | Methods, Compositions, and Kits for Identifying Regions of Genomic DNA Bound to a Protein | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 17774452 | METHODS OF DETECTING A FUSION GENE ENCODING A NEOANTIGEN | Non-Final OA | Foundation Medicine, Inc. |
| 18044289 | IMPROVED HIGH EFFICIENCY TARGETED IN SITU GENOME-WIDE PROFILING | Final Rejection | Fred Hutchinson Cancer Center |
| 17775932 | Methods and Kits using Internal Standards to Control for Complexity of Next Generation Sequencing(NGS) Libraries | Non-Final OA | The University of Toledo |
| 17628951 | METHODS FOR DIAGNOSING CANCER | Non-Final OA | Queen Mary University of London |
| 18073397 | 3 FLAP OKAZAKI FRAGMENTS AND USES THEREOF | Final Rejection | City of Hope |
| 18334327 | METHODS AND COMPOSITIONS FOR PERFORMING A DETECTION ASSAY | Non-Final OA | Mammoth Biosciences, Inc. |
| 18267622 | METHODS FOR CLASSIFYING A SAMPLE INTO CLINICALLY RELEVANT CATEGORIES | Final Rejection | MEDICOVER BIOTECH LTD |
| 18253687 | USE OF MATURE MITOCHONDRIAL TRANSCRIPTION FACTOR A (TFAM) FOR DIAGNOSING ORGAN DYSFUNCTIONS | Final Rejection | Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy